In the present study, we identified a cause of the electrophysiological abnormality in our AD models which overexpressed mutant PS1, screened the FDA-approved chemical libraries using our AD models, and examined whether the application of Aβ inhibitors can lead to the recovery of synaptic dysfunction. The gene discussed is PSEN1; the disease is Alzheimer disease.